These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3257900)

  • 1. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models.
    Eggermont AM; Sugarbaker PH; Marquet RL; Jeekel J
    Cancer Immunol Immunother; 1988; 26(1):23-30. PubMed ID: 3257900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM; Sugarbaker PH
    Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
    Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
    Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2].
    Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H
    No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo treatment with interferon causes augmentation of IL-2 induced lymphokine-activated killer cells in the organs of mice.
    Puri RK; Leland P
    Clin Exp Immunol; 1991 Aug; 85(2):317-25. PubMed ID: 1713814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
    Flexman JP; Manning LS; Robinson BW
    Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM; Steller EP; Ottow RT; Matthews W; Sugarbaker PH
    J Natl Cancer Inst; 1987 Nov; 79(5):983-90. PubMed ID: 3500357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the donors' clinical status on in vitro and in vivo tumor-cytotoxic activation of interleukin-2-exposed lymphocytes and their circulation in different organs.
    Rodolfo M; Salvi C; Parmiani G
    Cancer Immunol Immunother; 1989; 28(2):136-42. PubMed ID: 2783888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor activity of cyclophosphamide and ABPP in the treatment of established and advanced tumors in murine tumor models.
    Eggermont AM; Sugarbaker PH; Marquet RL; Jeekel J
    Cancer Immunol Immunother; 1987; 25(1):16-24. PubMed ID: 3594490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Injection of interleukin-2 (IL-2) into the tumor-bearer's spleen augments lymphokine-activated killer (LAK) activity in vitro and inhibits tumor metastasis].
    Okuno K; Ohnishi H; Takagi H; Nakamura T; Kokudo S; Yasutomi M
    Nihon Geka Gakkai Zasshi; 1987 Jul; 88(7):802-7. PubMed ID: 3499562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo.
    Lafreniere R; Rosenstein MS; Rosenberg SA
    J Immunol Methods; 1986 Nov; 94(1-2):37-49. PubMed ID: 2878049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.
    Ettinghausen SE; Puri RK; Rosenberg SA
    J Natl Cancer Inst; 1988 Apr; 80(3):177-88. PubMed ID: 3258039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.